Carlo Giulioni

Dr. Carlo Giulioni

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
SYSteffi Kar Kei Yuen
Steffi Kar Kei Yuen
Olivier TraxerOlivier Traxer
Olivier Traxer
MWMarcelo Langer Wroclawski
Marcelo Langer Wroclawski
NGNariman Gadzhiev
Nariman Gadzhiev
CCChu Ann Chai
Chu Ann Chai
Vineet GauharVineet Gauhar
Vineet Gauhar
The ureteral access sheath (UAS) has been a boon and a bane in flexible ureteroscopy (FURS), with its merits and demerits well established. Its design and dimensions were instrumental in reshaping the way flexible scopes were used and were key adjuncts to establishing retrograde intrarenal surgery (RIRS) as a standard of care in the endourological management of renal stones. With the ever-changing landscape of RIRS over the decades shaped by technological advancements in lasers and flexible scopes, the UAS has also continuously evolved. The utility of suction in endourology has recently changed the way RIRS is performed and is a game changer for FURS outcomes. With strong clinical and experimental evidence to support its use, the UAS has undergone a transformative change in the recent past, with its ability to monitor intrarenal pressure and provide a superior vacuum-cleaner effect that improves the trifecta of RIRS, namely an improved single-stage stone-free rate (SFR), minimise complications, and reduce reinterventions. Our comprehensive review outlines the key clinical and experimental evidence and traces the developments that were key to modifying the traditional UAS into a flexible and navigable suction ureteric access sheath (FANS) and highlights how the design and modifications, in turn, influence the ability to push the boundaries of RIRS.

1 January 2023 in The World Journal of Men's Health
Verified
Journal Article
Open access
PDF file
RSRupin Shah
Rupin Shah
Ashok AgarwalAshok Agarwal
Ashok Agarwal
PKParviz Kavoussi
Parviz Kavoussi
ARAmarnath Rambhatla
Amarnath Rambhatla
Ramadan SalehRamadan Saleh
Ramadan Saleh
Giovanni Maria ColpiGiovanni Maria Colpi
Giovanni Maria Colpi
Shah R, et al. World J Mens Health. 2023 Jan;41(1):164-197. https://doi.org/10.5534/wjmh.220048

18 July 2022 in Andrology
Verified
Journal Article
Open access
CGCarlo Giulioni
Carlo Giulioni
VMValentina Maurizi
Valentina Maurizi
DCDaniele Castellani
Daniele Castellani
SSSimone Scarcella
Simone Scarcella
ESEdlira Skrami
Edlira Skrami
AGAndrea Benedetto Galosi
Andrea Benedetto Galosi
Background: The environment plays a key role in male infertility, changing the incidence in various populations, and pesticides are one of the most studied hazards. The use of the latter has never decreased, jeopardizing the safety of workers and the general population.Objective: Our purpose was to summarize the results of studies discussing the association between pesticides and male fertility.Methods: A comprehensive literature search was performed through MEDLINE via PubMed, Scopus, and Web of Science. Only human studies were considered. Semen parameters and DNA integrity were considered to evaluate the effect of pesticides on men.Results: A total of 64 studies that investigated their impact in terms of semen parameters (51 studies) and chromatin and DNA integrity (25 studies) were included. The most frequently affected parameters were total sperm count, sperm motility, and sperm morphology, although a reduction in ejaculate volume and concentration occur in several cases. A tangible worsening of semen quality was associated with organochlorines and organophosphates. Furthermore, pesticide exposure, especially pyrethroids, was related to a higher DNA fragmentation index and chromosome aneuploidy in most articles.Conclusion: The epidemiological evidence supports the association between pesticides and male fertility for workers and the exposed population in terms of semen quality, DNA fragmentation, and chromosome aneuploidy.


16 June 2025 in The Journal of Liquid Biopsy
Verified
Journal Article
Open access
FCFelice Crocetto
Felice Crocetto
MMMichele Musone
Michele Musone
SCStefano Chianese
Stefano Chianese
PCPaolo Conforti
Paolo Conforti
GSGaetano Digitale Selvaggio
Gaetano Digitale Selvaggio
Daniela TerraccianoDaniela Terracciano
Daniela Terracciano
Prostate cancer (PCa) is one of the most prevalent malignancies in men, characterized by high clinical and molecular heterogeneity. Despite the widespread use of prostate-specific antigen (PSA) for diagnosis and monitoring, its limited specificity and sensitivity necessitate the development of more accurate biomarkers. This review provides a comprehensive overview of current and emerging diagnostic, prognostic, and predictive biomarkers in PCa, highlighting their clinical applications and future perspectives. PSA, though historically central in PCa screening, lacks tumor specificity, often leading to unnecessary biopsies or missed aggressive cancers. Recent blood-based biomarkers, such as the Prostate Health Index (PHI) and 4Kscore, improve specificity by integrating PSA isoforms or kallikrein protein levels with clinical parameters. Urine-based biomarkers like PCA3 and SelectMDx further enhance diagnostic precision, particularly in distinguishing high-grade tumors, and show potential in active surveillance settings. Prognostic markers such as Bcl-2, Ki-67, and EZH2, alongside genetic alterations like MCM7 and 8q gain, help stratify patients by tumor aggressiveness and risk of recurrence. Liquid biopsies, including circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), offer non-invasive alternatives for molecular profiling, especially in metastatic castration-resistant PCa (mCRPC), and can identify actionable alterations such as BRCA1/2 or ATM mutations. Emerging technologies such as machine learning and single-cell omics are reshaping biomarker discovery. Artificial intelligence-driven models, like the replication stress signature (RSS), show promise in predicting relapse and therapeutic response. Single-cell RNA sequencing and spatial transcriptomics have deepened our understanding of PCa heterogeneity, tumour microenvironment, and resistance mechanisms. Furthermore, novel biomarkers, including exosome RNAs and immune-related markers (PD-L1, SOX2, TcellinfGEP), offer insights into tumour progression and immunotherapeutic potential. The urinary and gut microbiomes are also being explored for their diagnostic and prognostic roles in PCa. In conclusion, integrating advanced molecular tools and biomarker-guided platforms into clinical practice can significantly enhance early detection, personalized treatment, and monitoring in prostate cancer, paving the way for precision oncology.

1 August 2024 in International braz j urol
Verified
Journal Article
Open access
PDF file
CGCarlo Giulioni
Carlo Giulioni
DFDemetra Fuligni
Demetra Fuligni
CBCarlo Brocca
Carlo Brocca
DRDeepak Ragoori
Deepak Ragoori
BCBen Hall Chew
Ben Hall Chew
DCDaniele Castellani
Daniele Castellani
To assess the incidence of the most common intra- and early postoperative complications following RIRS in a large series of patients with kidney stones.